CARsgen Therapeutics Holdings Limited (CRTHF)

1.6700 0.0000 (0.00%) At close: 10:31AM EDT

CARsgen Therapeutics Holdings Limited

No. 466 Yindu Road
1st Floor Building 2 Xuhui District
Shanghai
China
86 21 6450 1828
https://www.carsgen.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 516

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Zonghai Li M.D., Ph.D.	Co-Founder, CEO, Chief Scientific Officer & Chairman of the Board	275.26k	N/A	1974
Dr. Huamao Wang Ph.D.	Co-Founder, COO & Executive Director	295.01k	N/A	1977
Dr. Hua Jiang	Executive Director	317.8k	N/A	1979
Dr. Hong Ma	Senior Vice President of Clinical Development	N/A	N/A	1972
Dr. Leigh Hsu	Senior Vice President of Business Development	N/A	N/A	1971
Dr. Raffaele Baffa M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1960
Dr. Sylvie Peltier	Senior Vice President of Global Regulatory Affairs	N/A	N/A	1963
Mr. Wing Yat Lui	Company Secretary	N/A	N/A	1990

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in Phase I clinical trial for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors; and KJ-C2320 for acute myeloid leukemia that is in pre-clinical stage. Further, it develops AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company has a license agreement with HK Inno.N Corporation to develop and commercialize CT032 for the treatment of CD19. The company was founded in 2014 and is headquartered in Shanghai, China.

Corporate Governance

CARsgen Therapeutics Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.